LONDON, October 30 /PRNewswire/ --
Chiltern, a leading global clinical research organization (CRO), today announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States. From February 2008 the combined operation will be known exclusively as 'Chiltern'.
Established in 1989 by Dr. Robert Vann, John Vann and Ben Essary, CTMS has extensive experience conducting clinical trials in a wide variety of therapeutic areas with an emphasis on respiratory, gastrointestinal, central nervous system, infectious disease and ophthalmology indications. The company employs 190 people located in offices in Bristol and Winston-Salem, NC. John Vann, previously President and CEO of CTMS, today assumes overall leadership of Chiltern's U.S. operations, becoming Executive Vice-President Americas. Dr Robert Vann retires after a long and successful career in clinical research.
"We are looking forward to bringing together the complementary strengths and resources of Chiltern and CTMS," said Glenn Kerkhof, Chiltern's Chief Executive Officer. "The acquisition of CTMS significantly increases our presence and expertise within the US and strengthens Chiltern's position as a global CRO. CTMS and Chiltern have compatible cultures and are equally focused on delivering high quality services to the pharmaceutical, device and biotech industries. Detailed planning for the integration of our operations is underway and we are very confident of a smooth transition for customers, suppliers and employees alike."
"We are delighted to have found in Chiltern a buyer that not only shares our commitment to excellence in clinical research and service delivery to clients, but also provides our employees with opportunities for growth and participation internationally," said John Vann. "We have been struck throughout by the compatible nature of our organizations and the essentially seamless way we can bring them together. We are excited by the quality, depth and range of services we will be bringing our clients and are proud to be part of the expanded Chiltern team."
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1100 people with 20 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.
For More Information Contact: Catherine Lemercier Richard Baptista Chiltern International, Inc. Chiltern International Ltd. 2111 Palomar Airport Road 171 Bath Road Suite 200 Slough Carlsbad Berkshire CA 92011 SL1 4AA USA UNITED KINGDOM Tel: +1-760-707-5025 Tel: +44-(0)-1753-512-000 Fax: +1-760-707-5022 Fax: +44-(0)-1753-511-116 Email: Catherine.Lemercier@chiltern.com Email: Richard.Baptista@chiltern.com Chiltern: Understanding Development
Web site: http://www.chiltern.com
Catherine Lemercier, +1-760-707-5025, fax, +1-760-707-5022, Catherine.Lemercier@chiltern.com, or Richard Baptista, +44-(0)-1753-512-000, fax, +44-(0)-1753-511-116, Richard.Baptista@chiltern.com, both of Chiltern International Ltd.